StockVS

Aimei Health Technology Co., Ltd (AFJKU) Analyse boursière

Services Financiers

Aimei Health Technology Co., Ltd

$46.04

$-4.02 (-8.03%)

Dernière mise à jour : 26 mai 2026

Historique des Prix

Analyse

Présentation de l'entreprise

Aimei Health Technology Co., Ltd is an entity operating within the financial services sector, specifically classified under the industry of shell companies, which indicates a corporate structure designed primarily for business combination activities rather than ongoing operational revenue generation. The company's business description clarifies that it lacks significant operational assets and instead intends to pursue a merger, share exchange, asset acquisition, stock purchase, or reorganization with one or more target businesses, including potential acquisitions of small-cap entities in the biopharmaceutical space. Regarding its scale, the available factual data indicates that the market capitalization is N/A, the annual revenue is N/A, and the employee count is N/A, reflecting the absence of traditional operational metrics typical of mature enterprises. These missing valuation and revenue figures suggest that the company's current position is defined by its potential for future restructuring rather than established market dominance or historical financial performance, as it remains in a transitional phase awaiting a definitive business combination to establish a measurable market presence.

Santé financière

The financial statements for the trailing twelve months (TTM) report a net income of $1.41M while revenue remains N/A, a disparity that reveals a cost structure disconnected from current operational sales or significant revenue generation, as the profit margin stands at 0.0%. The company reports a free cash flow of $269,617, which provides a measure of financial flexibility that allows for potential investment in acquisition targets or operational restructuring despite the lack of reported revenue. All three margin metrics—gross margin, operating margin, and profit margin—are recorded at 0.0%, indicating that the company is not currently generating profit from its core activities or that its financial reporting does not reflect standard operational profitability associated with revenue-generating businesses. In terms of liquidity and leverage, the company holds cash of $2,979 against a total debt obligation of $1.66M, resulting in a current ratio of 0.01 which signals severe short-term liquidity constraints and an inability to meet current liabilities with current assets. The return on assets (ROA) is -1.0%, while return on equity (ROE) is N/A, metrics that collectively reveal that management is currently ineffective at generating returns on the company's asset base and equity capital, a common characteristic of shell companies awaiting a merger.

Évaluation de la valorisation

The trailing P/E ratio and forward P/E ratio are both listed as N/A, implying that the market cannot currently assess the company's earnings trajectory based on historical or projected earnings per share due to the absence of reported revenue and the specific accounting treatment of shell entities. The price-to-book ratio is reported at -63.13, a negative figure that indicates the market is valuing the company's equity at a level that does not align with its book value, often seen when liabilities exceed assets or when the business model does not support traditional book value valuation multiples. Alternative valuation metrics such as the price-to-sales ratio and EV/EBITDA are also N/A, suggesting that these standard comparative tools are inapplicable for a company that has not yet generated significant sales or positive EBITDA from its intended business combinations. The stock's price volatility is characterized by a 52-week high of $80.00 and a 52-week low of $7.60, placing the current trading environment within a highly compressed range relative to its historical extremes. The beta value of -1.50 further highlights the company's unique volatility profile, indicating that its price movements are inversely correlated with the broader market and exhibit significantly higher sensitivity to market shifts than a standard equity investment.

Growth & Income

The growth profile of the company shows an earnings growth rate of -30.2% year-over-year, while revenue growth is N/A, indicating that the reported earnings have contracted significantly in the most recent period, though the absence of revenue data prevents a direct comparison of growth rates between income and sales. Since the company does not pay dividends, the dividend yield and payout ratio are both N/A, meaning the firm currently retains all available earnings rather than distributing income to shareholders. This retention strategy is consistent with the profile of a shell company that must conserve capital for the upcoming business combination rather than rewarding investors with income distributions. The overall growth and income profile is therefore defined by earnings contraction in the absence of revenue, a reinvestment of all profits into potential acquisitions, and a lack of dividend income, reflecting a high-risk, high-potential restructuring phase rather than a mature growth or income generation stage.

Comparaison avec les pairs

Aimei Health Technology Co., Ltd (AFJKU) opère dans le secteur Sociétés Écrans. Voici comment il se compare à ses pairs les plus proches par capitalisation boursière :

Entreprise Ticker Cap. Boursière Ratio P/E
Aimei Health Technology Co., Ltd AFJKU N/A N/A
Twenty One Capital, Inc. XXI $2.49B N/A
Churchill Capital Corp X CCCX $711.00M N/A
Drugs Made In America Acquisition II Corp. DMII $641.46M 77.5

Le ratio P/E moyen du secteur Sociétés Écrans est de 82.8x. Aimei Health Technology Co., Ltd se négocie à un P/E de N/A.

Cette analyse est générée par IA à titre informatif uniquement et ne constitue pas un conseil financier. Les données peuvent être retardées ou inexactes. Faites toujours vos propres recherches et consultez un conseiller financier qualifié avant de prendre des décisions d'investissement.

À propos de Aimei Health Technology Co., Ltd

Aimei Health Technology Co., Ltd does not have significant operations. The company intends to effect a merger, share exchange, asset acquisition stock purchase, reorganization, or similar business combination with one or more businesses. It also intends to acquire small cap businesses in the biopharmaceutical, medical technology and device industries, as well as in the diagnostic and other services sector. Aimei Health Technology Co., Ltd was incorporated in 2023 and is based in New York, New York.

La description de l'entreprise est affichée en anglais.

Statistiques Clés

Capitalisation
N/A
Ratio P/E
N/A
Plus Haut 52 Sem.
$80.00
Plus Bas 52 Sem.
$7.60
Volume Moyen
76
Bêta
0.46

Données fournies par Yahoo Finance via yfinance. Mis à jour quotidiennement.

Info Entreprise

Bourse
NASDAQ
Pays
United States